Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer.
Hearn JWD, Sweeney CJ, Almassi N, Reichard CA, Reddy CA, Li H, Hobbs B, Jarrard DF, Chen YH, Dreicer R, Garcia JA, Carducci MA, DiPaola RS, Sharifi N. Hearn JWD, et al. Among authors: reichard ca. JAMA Oncol. 2020 Apr 1;6(4):e196496. doi: 10.1001/jamaoncol.2019.6496. Epub 2020 Apr 9. JAMA Oncol. 2020. PMID: 32053149 Free PMC article. Clinical Trial.
HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study.
Hearn JWD, AbuAli G, Reichard CA, Reddy CA, Magi-Galluzzi C, Chang KH, Carlson R, Rangel L, Reagan K, Davis BJ, Karnes RJ, Kohli M, Tindall D, Klein EA, Sharifi N. Hearn JWD, et al. Among authors: reichard ca. Lancet Oncol. 2016 Oct;17(10):1435-1444. doi: 10.1016/S1470-2045(16)30227-3. Epub 2016 Aug 27. Lancet Oncol. 2016. PMID: 27575027 Free PMC article.
Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
Nyame YA, Almassi N, Haywood SC, Greene DJ, Ganesan V, Dai C, Zabell J, Reichard C, Arora H, Zampini A, Crane A, Hettel D, Elshafei A, Fareed K, Stein RJ, Berglund RK, Gong M, Jones JS, Klein EA, Stephenson AJ. Nyame YA, et al. J Urol. 2017 Sep;198(3):591-599. doi: 10.1016/j.juro.2017.03.123. Epub 2017 Mar 24. J Urol. 2017. PMID: 28347770
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomy.
Wilkins LJ, Tosoian JJ, Reichard CA, Sundi D, Ranasinghe W, Alam R, Schwen Z, Reddy C, Allaf M, Davis JW, Chapin BF, Ross AE, Klein EA, Nyame YA. Wilkins LJ, et al. Among authors: reichard ca. Cancer. 2021 May 1;127(9):1425-1431. doi: 10.1002/cncr.33419. Epub 2021 Mar 15. Cancer. 2021. PMID: 33721334 Free article.
Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C, Ganesan V, Zabell J, Nyame YA, Almassi N, Greene DJ, Hettel D, Reichard C, Haywood SC, Arora H, Zampini A, Crane A, Li J, Elshafei A, Magi-Galluzzi C, Stein RJ, Fareed K, Gong M, Jones JS, Klein EA, Stephenson AJ. Dai C, et al. J Urol. 2018 Feb;199(2):445-452. doi: 10.1016/j.juro.2017.08.006. Epub 2017 Aug 5. J Urol. 2018. PMID: 28789947
40 results